Research Study

Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS), Comparing Rivaroxaban 15 mg Once Daily With Aspirin 100 mg
Principal Investigator 
Thalia Field

Overview

Body Locations and Systems 
Stroke
ClinicalTrials.gov# 
NCT02313909
Status 
Recruiting
Study Start/End 
Oct 9, 2015 to Dec 30, 2017
Locations 
Diamond Health Care Centre, GF Strong Rehabilitation Centre, UBC Hospital, Vancouver Community, Vancouver General Hospital
Name/Title 
Karina Murray, Research Coordinator
Phone 
604-875-4554 ext.1
Purpose of Study 

This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified. These strokes are likely due to a blood clot and therefore, can be called embolic stroke of undetermined source. The abbreviation is ESUS. The study will compare 2 blood thinners. Patients will be randomly assigned to either Rivaroxaban 15 mg or Aspirin 100 mg and the study is intended to show, if patients given rivaroxaban have fewer blood clots in the brain (stroke) or in other blood vessels.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.